Q3 Earnings Estimate for Biogen Issued By Leerink Partnrs

Key Points

• Biogen's Q3 2025 EPS estimate was raised by Leerink Partners from $3.86 to $3.91, reflecting positive expectations for the biotechnology company's earnings.
• The stock currently has an average rating of "Hold" among analysts, with a consensus price target of $179.96.
• Biogen reported earnings of $5.47 per share for its last quarter, surpassing estimates and showing a revenue increase of 7.3% year-over-year.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Biogen in a research note issued to investors on Monday, October 6th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings per share of $3.91 for the quarter, up from their prior forecast of $3.86. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen's FY2025 earnings at $15.60 EPS, FY2027 earnings at $16.30 EPS, FY2028 earnings at $15.85 EPS and FY2029 earnings at $21.20 EPS.

BIIB has been the topic of a number of other research reports. Needham & Company LLC reissued a "hold" rating on shares of Biogen in a report on Wednesday, September 24th. Wall Street Zen raised shares of Biogen from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 28th. William Blair reissued an "outperform" rating on shares of Biogen in a report on Wednesday, September 24th. Truist Financial began coverage on shares of Biogen in a report on Monday, July 21st. They issued a "hold" rating and a $142.00 price objective on the stock. Finally, Rothschild & Co Redburn raised their price objective on shares of Biogen from $149.00 to $150.00 and gave the stock a "neutral" rating in a report on Monday. Eleven equities research analysts have rated the stock with a Buy rating, twenty have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $179.96.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $150.97 on Thursday. The firm's 50-day moving average price is $139.49 and its 200-day moving average price is $131.13. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. The company has a market cap of $22.14 billion, a PE ratio of 14.43, a PEG ratio of 1.20 and a beta of 0.13. Biogen has a 52-week low of $110.04 and a 52-week high of $194.13.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. The firm had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.32 billion. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The business's quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm posted $5.28 EPS. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 517 shares of Biogen stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the transaction, the insider owned 5,772 shares of the company's stock, valued at $770,850.60. The trade was a 8.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently modified their holdings of the stock. Elevation Point Wealth Partners LLC bought a new stake in shares of Biogen during the second quarter valued at approximately $25,000. Opal Wealth Advisors LLC bought a new stake in shares of Biogen during the first quarter valued at approximately $26,000. Vision Financial Markets LLC bought a new stake in shares of Biogen during the first quarter valued at approximately $27,000. Greykasell Wealth Strategies Inc. bought a new stake in shares of Biogen during the first quarter valued at approximately $27,000. Finally, Rothschild Investment LLC raised its position in shares of Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company's stock valued at $28,000 after buying an additional 88 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.